Rat and Canine Microphysiological Systems of the Kidney Proximal Tubule for Chemical Toxicity Screening
用于化学毒性筛查的大鼠和犬肾近端小管微生理系统
基本信息
- 批准号:10363049
- 负责人:
- 金额:$ 87.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-14 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAccountingAcute Kidney FailureAdvanced DevelopmentAmericanAnimal ModelAnimal TestingAnimalsApicalApplications GrantsBackBiological AssayBiological ModelsCanis familiarisCell Culture SystemCell Culture TechniquesCell SurvivalCellsChemicalsClinicalClinical MedicineDataDevicesEnvironmentExhibitsExperimental Animal ModelExposure toFoodFutureGenesGoalsHarvestHealthHepatocyteHousehold ProductsHumanIn VitroInflammationInjectionsInjuryInjury to KidneyKidneyLaboratoriesLaboratory cultureLipidsLocationMedicineMicrofluidic MicrochipsMicrofluidicsModelingMoldsOrganOutcomePerformancePharmaceutical PreparationsPhasePhase III Clinical TrialsPlayPoisonPolymyxin BPreclinical TestingProcessProtocols documentationProximal Kidney TubulesPublishingRattusRegulationRunningSeedsShippingShipsSiteStainsStructureSystemTechnologyTestingTimeToxic effectToxicologyTranslatingUp-RegulationVariantanimal databasebiological adaptation to stressdesigndrug developmentexperienceexperimental studyhazardhuman modelhuman tissuein vitro Modelin vivokidney cellmicrophysiology systemnephrogenesisnephrotoxicityorgan on a chipperformance testspredictive toolsprototyperat KIM-1 proteinresponse to injurysample collectionscreeningtooltoxicant
项目摘要
Project Summary
Humans are constantly exposed to a variety of chemicals via food, household products, medicines, and the
environment. The kidney is particularly susceptible to chemical damage; drug-induced nephrotoxicity is a major
health concern that contributes to 25% of all cases of severe acute kidney failure. Nephrotoxicity is also a
significant problem in drug development; it is a major cause of attrition late in the process, accounting for 19%
of failed Phase III clinical trials. The limitations of state-of-the-art animal models and in vitro tools for predicting
human nephrotoxicity are well acknowledged, which has sparked the development of advanced 3D in vitro
models of human tissues and organs, so called organ-on-chip systems (OOC) or microphysiological systems
(MPS). While progress with human-based MPS has been rapid, a translational gap remains between MPS data
and in vivo data. Therefore, comparing observations from animal-based MPS to in vivo animal data will inform
our ability to translate human MPS findings to clinical medicine.
This fast-track grant application proposes the development of kidney proximal tubule (KPT) MPS from two animal
species that are frequently used in kidney toxicity screening: rat and dog. Once successfully developed,
validated, and commercialized, the KPT-MPS will serve as an important new tool in chemical toxicity screening
and drug development, allowing cross-referencing animal-based MPS data with in vivo animal data, human-
based MPS data and clinical outcomes. It also has the potential to replace some animal testing, significantly
reducing the use of live animals in preclinical testing.
Phase I of the project is designed to establish robust KPT-MPS models from rat and dog. The project will leverage
the commercially available Nortis MPS platform and pre-established protocols for creating human based KPT-
MPS. Phase I/AIM 1 will demonstrate that proximal tubule cells from rat and dog form viable and structurally
complete proximal tubules and that these tubules exhibit a stress response when exposed to compounds that
are toxic to KPTs in vivo (Phase I/AIM 2). Feasibility requirements will be established in at least one of the two
species before the project progresses into Phase II. Phase II will focus on optimizing the rat and or dog KPT-
MPS prototypes and on developing assays for testing potentially nephrotoxic compounds (Phase II/AIM 1). For
these efforts we will leverage a new microfluidic chip made of an injection-molded thermoplastic material that
was developed for a human-based KPT-MPS. During Phase II/AIM 2, a panel of five compounds with published
species-specific nephrotoxicity for rat, dog, and human will be tested in the KPT-MPS with the goal to establish
correlation between KPT-MPS data and in vivo data in all three species. Phase II/AIM 3 is to demonstrate that
rat/dog KPT-MPSs can be shipped to future customers as a plug & play pre-seeded product.
项目摘要
人类通过食物、家用产品、药品和其他化学品不断暴露于各种化学品中。
环境肾脏特别容易受到化学损伤;药物引起的肾毒性是主要的
严重急性肾功能衰竭的所有病例中有25%是由这种健康问题引起的。肾毒性也是一种
药物开发中的一个重要问题;它是过程后期流失的主要原因,占19%
失败的III期临床试验最先进的动物模型和体外预测工具的局限性
人类肾毒性是众所周知的,这引发了先进的体外3D技术的发展
人体组织和器官的模型,所谓的器官芯片系统(OOC)或微生理系统
(MPS)。虽然基于人类的MPS进展迅速,但MPS数据之间仍存在翻译差距
和体内数据。因此,将基于动物的MPS的观察结果与体内动物数据进行比较,
我们将人类MPS发现转化为临床医学的能力。
这项快速拨款申请提出了从两种动物中开发肾近端小管(KPT)MPS,
经常用于肾毒性筛选的种属:大鼠和犬。一旦研制成功,
经过验证和商业化,KPT-MPS将成为化学毒性筛选的重要新工具
和药物开发,允许交叉引用基于动物的MPS数据与体内动物数据,人类-
基于MPS数据和临床结局。它也有可能取代一些动物试验,
减少在临床前试验中使用活体动物。
该项目的第一阶段旨在从大鼠和犬中建立稳健的KPT-MPS模型。该项目将利用
市售Nortis MPS平台和预先建立的用于创建基于人类的KPT的方案-
MPS。I期/AIM 1将证明来自大鼠和狗的近端小管细胞形成活性和结构
完整的近端小管,并且当暴露于
在体内对KPT有毒性(I期/AIM 2)。将在两个项目中的至少一个项目中确定可行性要求
在项目进入第二阶段之前,第二阶段将重点优化大鼠和/或犬KPT-
MPS原型和开发用于测试潜在肾毒性化合物的试验(II期/AIM 1)。为
通过这些努力,我们将利用一种新的由注塑热塑性材料制成的微流体芯片,
是为基于人类的KPT-MPS开发的。在II期/AIM 2期间,一组五种化合物,
将在KPT-MPS中检测大鼠、犬和人的种属特异性肾毒性,目的是确定
所有三个种属的KPT-MPS数据与体内数据之间的相关性。第二阶段/目标3是证明,
大鼠/狗KPT-MPS可以作为即插即用的预接种产品运送给未来的客户。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas Neumann其他文献
Thomas Neumann的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas Neumann', 18)}}的其他基金
A liver-on-chip platform to evaluate panels of clinically relevant gene variants for screening of xenobiotic compounds
用于评估临床相关基因变异组以筛选异生化合物的肝脏芯片平台
- 批准号:
10738215 - 财政年份:2023
- 资助金额:
$ 87.61万 - 项目类别:
Rat and Canine Microphysiological Systems of the Kidney Proximal Tubule for Chemical Toxicity Screening
用于化学毒性筛查的大鼠和犬肾近端小管微生理系统
- 批准号:
10405579 - 财政年份:2021
- 资助金额:
$ 87.61万 - 项目类别:
Rat and Canine Microphysiological Systems of the Kidney Proximal Tubule for Chemical Toxicity Screening
用于化学毒性筛查的大鼠和犬肾近端小管微生理系统
- 批准号:
10086753 - 财政年份:2020
- 资助金额:
$ 87.61万 - 项目类别:
Development of pharmacokinetic assays utilizing an organ-on-chip model of the human kidney proximal tubule
利用人肾近端小管的器官芯片模型开发药代动力学测定
- 批准号:
10210318 - 财政年份:2019
- 资助金额:
$ 87.61万 - 项目类别:
Development of pharmacokinetic assays utilizing an organ-on-chip model of the human kidney proximal tubule
利用人肾近端小管的器官芯片模型开发药代动力学测定
- 批准号:
10173393 - 财政年份:2019
- 资助金额:
$ 87.61万 - 项目类别:
Organ-on-Chip Approach for Assessing Tissue-specific SARS-CoV-2 Infection and Response to Antiviral Therapy
用于评估组织特异性 SARS-CoV-2 感染和抗病毒治疗反应的器官芯片方法
- 批准号:
10171540 - 财政年份:2019
- 资助金额:
$ 87.61万 - 项目类别:
Microfluidic Platform for Stem Cell Applications
用于干细胞应用的微流控平台
- 批准号:
9247537 - 财政年份:2016
- 资助金额:
$ 87.61万 - 项目类别:
A microfluidic quality-control assay for stem-cell derived therapies
干细胞衍生疗法的微流体质量控制测定
- 批准号:
9045158 - 财政年份:2016
- 资助金额:
$ 87.61万 - 项目类别:
A microfluidic platform for modeling drug transport and cell trafficking across the blood-brain barrier
用于模拟药物跨血脑屏障转运和细胞运输的微流体平台
- 批准号:
9356329 - 财政年份:2015
- 资助金额:
$ 87.61万 - 项目类别:
A microfluidic platform for modeling drug transport and cell trafficking across the blood-brain barrier
用于模拟药物跨血脑屏障转运和细胞运输的微流体平台
- 批准号:
9286282 - 财政年份:2015
- 资助金额:
$ 87.61万 - 项目类别:
相似海外基金
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 87.61万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
$ 87.61万 - 项目类别:
Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
- 批准号:
24K04974 - 财政年份:2024
- 资助金额:
$ 87.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
- 批准号:
23K01686 - 财政年份:2023
- 资助金额:
$ 87.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
- 批准号:
23K01692 - 财政年份:2023
- 资助金额:
$ 87.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
- 批准号:
23K01695 - 财政年份:2023
- 资助金额:
$ 87.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
- 批准号:
23K01713 - 财政年份:2023
- 资助金额:
$ 87.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
- 批准号:
2312319 - 财政年份:2023
- 资助金额:
$ 87.61万 - 项目类别:
Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
- 批准号:
23K01715 - 财政年份:2023
- 资助金额:
$ 87.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
$ 87.61万 - 项目类别: